Get started
Work

MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results

Year: 2021
Type: conference-abstract
DOI: 10.1016/s2152-2650(21)01798-5
Authors: Andrew H. Wei, Jacqueline S. Garcia, Uma Borate, Chun Yew Fong, Maria R Baer, Daniel Nowak, Pierre Peterlin, Joseph Jurcic, Meagan A. Jacoby, Uwe Platzbecker, Olatoyosi Odenike, Ilona Cunningham, Ying Zhou, David Hoffman, Leah Hogdal, Kiran Naqvi, Steve Kye, Guillermo Garcia-Manero
Institutions: The Alfred Hospital, Monash University, Dana-Farber Cancer Institute, OHSU Knight Cancer Institute, Austin Health, Olivia Newton-John Cancer Research Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Heidelberg University, Medizinische Fakultät Mannheim, Centre Hospitalier Universitaire de Nantes, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Barnes-Jewish Hospital, Washington University in St. Louis, University Hospital Leipzig, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, The University of Sydney, Concord Repatriation General Hospital, AbbVie (United States), Genentech, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W3197688599
Cites:
Cited by: 4
Related to: 10